{"id":"risperidone-long-acting-injectable","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site pain or reaction"},{"rate":"15-25","effect":"Weight gain"},{"rate":"10-20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"20-30","effect":"Prolactin elevation (galactorrhea, amenorrhea)"},{"rate":"10-15","effect":"Sedation"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"15-25","effect":"Metabolic syndrome (dyslipidemia, hyperglycemia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The long-acting injectable formulation provides sustained drug delivery over weeks, improving medication adherence.","oneSentence":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:23.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (maintenance treatment)"},{"name":"Irritability associated with autism spectrum disorder"},{"name":"Aggression and behavioral disturbances in patients with psychotic disorders"}]},"trialDetails":[{"nctId":"NCT05766007","phase":"","title":"Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-08-01","conditions":"Schizophrenia, Psychosis, Mania","enrollment":125},{"nctId":"NCT05480046","phase":"","title":"Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2022-10-18","conditions":"Schizophrenia","enrollment":275},{"nctId":"NCT00539071","phase":"PHASE4","title":"High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":160},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03713658","phase":"PHASE4","title":"A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-18","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05473741","phase":"","title":"Risk of Breakthrough Symptoms With Long-Acting Injectable Medications","status":"UNKNOWN","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-01-09","conditions":"Schizophrenia, Schizophrenia Relapse","enrollment":180},{"nctId":"NCT00330551","phase":"PHASE4","title":"Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT03919994","phase":"","title":"Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2019-03-28","conditions":"Schizophrenia","enrollment":338},{"nctId":"NCT01451736","phase":"PHASE4","title":"Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-10","conditions":"Schizophrenia (Recent-onset)","enrollment":146},{"nctId":"NCT05179525","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone.","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2021-03-09","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT03527186","phase":"PHASE1","title":"Comparative Bioavailability of Risperidone","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2018-07-09","conditions":"Schizophrenia","enrollment":81},{"nctId":"NCT03978832","phase":"PHASE4","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-06-28","conditions":"Schizophrenia","enrollment":69},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00130923","phase":"PHASE4","title":"Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-09","conditions":"Schizophrenia, Psychotic Disorders, Substance Abuse","enrollment":95},{"nctId":"NCT02634320","phase":"PHASE4","title":"A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-12","conditions":"Schizophrenia","enrollment":51},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT02203838","phase":"PHASE3","title":"Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-06","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT00330863","phase":"PHASE4","title":"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2006-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":357},{"nctId":"NCT00314327","phase":"PHASE4","title":"Optimizing Response in Psychosis Study","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2006-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":1},{"nctId":"NCT03390712","phase":"","title":"Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection","status":"UNKNOWN","sponsor":"Réseau de Santé Vitalité Health Network","startDate":"2018-01-02","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":328},{"nctId":"NCT00571688","phase":"PHASE4","title":"Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder?","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2007-11","conditions":"Bipolar Disorder","enrollment":50},{"nctId":"NCT02687984","phase":"PHASE1","title":"PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-02","conditions":"Schizophrenia","enrollment":44},{"nctId":"NCT00044655","phase":"PHASE4","title":"Switching Medication to Treat Schizophrenia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2001-07","conditions":"Schizophrenia","enrollment":219},{"nctId":"NCT00177164","phase":"PHASE3","title":"Risperdal Consta for Bipolar Disorder","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2003-11","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT01698216","phase":"","title":"Switching From Consta® to Sustenna® in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-12","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT02087579","phase":"PHASE1","title":"Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02","conditions":"Psychotic Disorders, Schizophrenia, Bipolar Disorder","enrollment":305},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT00644852","phase":"","title":"Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2007-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":342},{"nctId":"NCT00821600","phase":"PHASE1","title":"Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2008-12","conditions":"Psychotic Disorders, Schizophrenia","enrollment":24},{"nctId":"NCT00391222","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-11","conditions":"Bipolar Disorder","enrollment":585},{"nctId":"NCT01894984","phase":"","title":"An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia","status":"TERMINATED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2007-01","conditions":"Schizophrenia","enrollment":640},{"nctId":"NCT00378092","phase":"PHASE4","title":"A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode","status":"COMPLETED","sponsor":"Janssen Cilag N.V./S.A.","startDate":"2006-04","conditions":"Schizophrenia","enrollment":33},{"nctId":"NCT01726335","phase":"PHASE4","title":"Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2006-01","conditions":"Schizophrenia","enrollment":53},{"nctId":"NCT00269919","phase":"PHASE4","title":"An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2005-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT00216476","phase":"PHASE3","title":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2004-10","conditions":"Schizophrenia, Psychotic Disorders","enrollment":753},{"nctId":"NCT00246194","phase":"","title":"Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"2004-09","conditions":"Schizophrenia","enrollment":532},{"nctId":"NCT00294008","phase":"","title":"A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2004-12","conditions":"Schizophrenia, Tranquilizing Agents, Mental Disorders","enrollment":230},{"nctId":"NCT00992407","phase":"PHASE4","title":"An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-12","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00526877","phase":"PHASE4","title":"An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2007-07","conditions":"Schizophrenia, Schizoaffective Disorders","enrollment":31},{"nctId":"NCT01181960","phase":"","title":"Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2010-08","conditions":"Schizophrenia, Bipolar Disorder","enrollment":1066},{"nctId":"NCT00132314","phase":"PHASE3","title":"Long-Acting Injectable Risperidone in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-09","conditions":"Schizoaffective Disorder, Schizophrenia","enrollment":382},{"nctId":"NCT00246259","phase":"PHASE4","title":"A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2004-10","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":77},{"nctId":"NCT00256997","phase":"PHASE4","title":"A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication","status":"TERMINATED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2006-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT01855074","phase":"PHASE4","title":"An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2007-11","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":80},{"nctId":"NCT00132678","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-02","conditions":"Bipolar Disorder","enrollment":559},{"nctId":"NCT00216671","phase":"PHASE4","title":"Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2005-11","conditions":"Schizophrenia","enrollment":220},{"nctId":"NCT00604279","phase":"PHASE3","title":"A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":452},{"nctId":"NCT01888107","phase":"PHASE3","title":"Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2005-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":347},{"nctId":"NCT01026285","phase":"","title":"InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-06","conditions":"Schizophrenia","enrollment":1085},{"nctId":"NCT00216580","phase":"PHASE3","title":"A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2004-02","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00216632","phase":"PHASE4","title":"A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2005-03","conditions":"Schizophrenia, Psychotic Disorders","enrollment":99},{"nctId":"NCT00774085","phase":"","title":"An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone","status":"COMPLETED","sponsor":"Janssen Cilag N.V./S.A.","startDate":"2004-11","conditions":"Schizophrenia","enrollment":408},{"nctId":"NCT00299702","phase":"PHASE4","title":"Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-02","conditions":"Schizophrenia, Psychotic Disorders","enrollment":355},{"nctId":"NCT00843687","phase":"PHASE3","title":"A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2005-09","conditions":"Schizophrenia","enrollment":188},{"nctId":"NCT00236587","phase":"PHASE3","title":"A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-11","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00236457","phase":"PHASE3","title":"A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2000-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":629},{"nctId":"NCT00236548","phase":"PHASE3","title":"Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Schizophrenia, Psychotic Disorders","enrollment":1},{"nctId":"NCT00828958","phase":"PHASE3","title":"Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-02","conditions":"Schizophrenia","enrollment":53},{"nctId":"NCT00297388","phase":"PHASE3","title":"A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT00236353","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"2002-05","conditions":"Schizophrenia, Psychotic Disorders","enrollment":86},{"nctId":"NCT00240708","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2004-06","conditions":"Schizophrenia","enrollment":205},{"nctId":"NCT00653406","phase":"PHASE1, PHASE2","title":"A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2002-11","conditions":"Schizophrenia","enrollment":29},{"nctId":"NCT00558298","phase":"PHASE3","title":"A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"2000-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":811},{"nctId":"NCT00261430","phase":"PHASE4","title":"A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"","conditions":"Schizophrenia","enrollment":650},{"nctId":"NCT00495118","phase":"PHASE3","title":"A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"2001-10","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":314},{"nctId":"NCT00369239","phase":"PHASE4","title":"Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-03","conditions":"Schizophrenia, Psychotic Disorders, Schizoaffective Disorder","enrollment":303},{"nctId":"NCT00246246","phase":"PHASE3","title":"A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"Janssen-Ortho Inc., Canada","startDate":"2004-01","conditions":"Bipolar Disorder","enrollment":48},{"nctId":"NCT00249223","phase":"PHASE3","title":"A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2000-01","conditions":"Schizophrenia, Psychotic Disorders","enrollment":641},{"nctId":"NCT00034775","phase":"PHASE3","title":"A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2001-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":141},{"nctId":"NCT00253136","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen, LP","startDate":"1999-11","conditions":"Schizophrenia, Psychotic Disorders","enrollment":458},{"nctId":"NCT00210691","phase":"PHASE3","title":"A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1999-12","conditions":"Schizophrenia","enrollment":273},{"nctId":"NCT00458367","phase":"","title":"RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2002-06","conditions":"Schizophrenia, Psychotic Disorders, Schizoaffective Disorder","enrollment":5296},{"nctId":"NCT00563017","phase":"NA","title":"Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2004-10","conditions":"Schizophrenia, Catatonic, Schizophrenia, Disorganized, Schizophrenia, Paranoid","enrollment":30},{"nctId":"NCT00283517","phase":"","title":"A Registry of Treatment Adherence for Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","startDate":"2003-09","conditions":"Schizophrenia, Psychotic Disorders","enrollment":2046},{"nctId":"NCT00216528","phase":"PHASE4","title":"A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2005-07","conditions":"Schizophrenia","enrollment":527},{"nctId":"NCT00284206","phase":"PHASE2","title":"A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2006-01","conditions":"Methamphetamine Dependence","enrollment":20},{"nctId":"NCT00287027","phase":"","title":"Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication","status":"TERMINATED","sponsor":"National Alliance on Mental Illness New Hampshire","startDate":"2006-02","conditions":"Psychotic Disorders","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperidone Long acting injectable","genericName":"Risperidone Long acting injectable","companyName":"Janssen Pharmaceutica N.V., Belgium","companyId":"janssen-pharmaceutica-n-v-belgium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (maintenance treatment), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}